GRFS · Nasdaq, OTC, OTC, OTC · CIK 0001438569

Grifols SA

Grifols SA’s most recent SEC filing in our snapshot is a Form 6-K filed on Jul 30, 2026. In fiscal 2024 (year ended Dec 31, 2024) it reported revenue of EUR 7.2B and net income of EUR 212.8M, according to its XBRL data on EDGAR. Its EDGAR record lists 0 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2024
EUR 7.2B
Net income, FY2024
EUR 212.8M
Form 4 filings on record, past 12 months
0

Company overview

Legal name (as filed)
Grifols SA
Tickers
GRFS, GIFLF, GIFOF, GIKLY
SEC Central Index Key (CIK)
0001438569
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
NEW YORK, NY
State or country of incorporation
—
Fiscal year ends
—
SEC filer category
Large accelerated filer
Position in SEC ticker list
#1332 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Grifols SA’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in EUR; the fiscal year is named for the calendar year in which it ends.

Revenue
EUR 5.3BFY2020EUR 4.9BFY2021EUR 6.1BFY2022EUR 6.6BFY2023EUR 7.2BFY2024
Net income
EUR 709.0MFY2020EUR 265.3MFY2021EUR 247.9MFY2022EUR 163.7MFY2023EUR 212.8MFY2024
GRFS annual results
ItemFY2020
ended Dec 31, 2020		FY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024
RevenueEUR 5.3BEUR 4.9BEUR 6.1BEUR 6.6BEUR 7.2B
Net incomeEUR 709.0MEUR 265.3MEUR 247.9MEUR 163.7MEUR 212.8M
Diluted EPSEUR 0.90EUR 0.28EUR 0.27EUR 0.06EUR 0.23
Total assetsEUR 15.3BEUR 19.2BEUR 21.2BEUR 21.0BEUR 21.4B
Cash and equivalentsEUR 444.8MEUR 655.5MEUR 548.0MEUR 523.1MEUR 974.7M

XBRL tags used: revenue = Revenue; netIncome = ProfitLoss; assets = Assets; eps = DilutedEarningsLossPerShare; cash = Cash. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

GRFS latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Apr 17, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Jul 30, 20266-KReport of a foreign private issuer· period Jul 30, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Grifols SA, by form type:

6-K ×32SCHEDULE 13G/A ×520-F ×2SCHEDULE 13G ×1
GRFS recent filings
FiledFormWhat it isOriginal
Jul 30, 20266-KReport of a foreign private issuer· period Jul 30, 2026Document · Index
Jul 29, 20266-KReport of a foreign private issuer· period Jul 28, 2026Document · Index
Jun 22, 20266-KReport of a foreign private issuer· period Jun 22, 2026Document · Index
Jun 18, 20266-KReport of a foreign private issuer· period Jun 18, 2026Document · Index
May 15, 20266-KReport of a foreign private issuer· period May 15, 2026Document · Index
May 14, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 7, 20266-KReport of a foreign private issuer· period May 7, 2026Document · Index
Apr 17, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Apr 14, 20266-KReport of a foreign private issuer· period Apr 14, 2026Document · Index
Mar 24, 20266-KReport of a foreign private issuer· period Mar 24, 2026Document · Index
Feb 26, 20266-KReport of a foreign private issuer· period Feb 26, 2026Document · Index
Feb 26, 20266-KReport of a foreign private issuer· period Feb 26, 2026Document · Index
Feb 17, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Feb 12, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jan 8, 20266-KReport of a foreign private issuer· period Jan 8, 2026Document · Index
Dec 16, 20256-KReport of a foreign private issuer· period Dec 16, 2025Document · Index
Nov 12, 2025SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Nov 4, 20256-KReport of a foreign private issuer· period Nov 4, 2025Document · Index
Sep 29, 20256-KReport of a foreign private issuer· period Sep 29, 2025Document · Index
Jul 30, 20256-KReport of a foreign private issuer· period Jul 30, 2025Document · Index
Jul 29, 20256-KReport of a foreign private issuer· period Jul 29, 2025Document · Index
Jul 29, 20256-KReport of a foreign private issuer· period Jul 29, 2025Document · Index
Jun 12, 20256-KReport of a foreign private issuer· period Jun 11, 2025Document · Index
Jun 5, 20256-KReport of a foreign private issuer· period Jun 5, 2025Document · Index
May 12, 20256-KReport of a foreign private issuer· period May 12, 2025Document · Index
May 6, 20256-KReport of a foreign private issuer· period May 6, 2025Document · Index
May 2, 20256-KReport of a foreign private issuer· period May 2, 2025Document · Index
Apr 11, 202520-FAnnual report of a foreign private issuer· period Dec 31, 2024Document · Index
Apr 9, 2025SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Apr 2, 20256-KReport of a foreign private issuer· period Apr 2, 2025Document · Index
Mar 31, 20256-KReport of a foreign private issuer· period Mar 31, 2025Document · Index
Mar 10, 20256-KReport of a foreign private issuer· period Mar 10, 2025Document · Index
Feb 27, 20256-KReport of a foreign private issuer· period Feb 27, 2025Document · Index
Feb 26, 20256-KReport of a foreign private issuer· period Feb 26, 2025Document · Index
Feb 26, 20256-KReport of a foreign private issuer· period Feb 26, 2025Document · Index
Feb 25, 20256-KReport of a foreign private issuer· period Feb 25, 2025Document · Index
Feb 14, 2025SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Dec 23, 20246-KReport of a foreign private issuer· period Dec 23, 2024Document · Index
Dec 11, 20246-KReport of a foreign private issuer· period Dec 12, 2024Document · Index
Dec 9, 20246-KReport of a foreign private issuer· period Dec 9, 2024Document · Index

Insider filing activity

0 Form 4 filings appear in Grifols SA’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in New York

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001438569 and XBRL company facts. Grifols SA on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.